Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Five Prime Thera (FPRX)

Five Prime Thera (FPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,769,736
  • Shares Outstanding, K 46,572
  • Annual Sales, $ 13,180 K
  • Annual Income, $ -84,330 K
  • 60-Month Beta 4.63
  • Price/Sales 134.26
  • Price/Cash Flow N/A
  • Price/Book 5.45
Trade FPRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.30
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/06/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility N/A
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.54
  • Number of Estimates 2
  • High Estimate -0.35
  • Low Estimate -0.72
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.60 +1.06%
on 04/05/21
38.01 -0.03%
on 04/15/21
+0.14 (+0.37%)
since 03/15/21
3-Month
13.63 +178.80%
on 01/21/21
38.90 -2.31%
on 03/09/21
+23.78 (+167.23%)
since 01/15/21
52-Week
2.61 +1,355.94%
on 04/16/20
38.90 -2.31%
on 03/09/21
+35.19 (+1,252.31%)
since 04/15/20

Most Recent Stories

More News
INVESTIGATION ALERT: Halper Sadeh LLP Investigates STAY, CUB, AEGN, FPRX; Shareholders are Encouraged to Contact the Firm

NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

STAY : 20.46 (unch)
CUB : 75.00 (+0.32%)
AEGN : 29.99 (-0.03%)
FPRX : 38.00 (+0.03%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of FRTA, AEGN, FPRX, and MIK Buyouts

WILMINGTON, Del., March 18, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

FRTA : 24.00 (+4.03%)
AEGN : 29.99 (-0.03%)
FPRX : 38.00 (+0.03%)
MIK : 21.97 (-0.14%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates WIFI, FFG, FPRX, PTVCA; Shareholders Are Encouraged to Contact the Firm

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

WIFI : 13.99 (+0.07%)
FFG : 60.99 (+0.03%)
FPRX : 38.00 (+0.03%)
PTVCA : 23.27 (+0.04%)
FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Five Prime Therapeutics (NasdaqGS: FPRX) to...

FPRX : 38.00 (+0.03%)
AMGN : 283.74 (+0.12%)
Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10,...

FPRX : 38.00 (+0.03%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates SVBI, FPRX, MIK, JCS; Shareholders Are Encouraged to Contact the Firm

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

SVBI : 13.63 (+5.66%)
FPRX : 38.00 (+0.03%)
MIK : 21.97 (-0.14%)
JCS : 8.18 (-7.99%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Five Prime Therapeutics, Inc. Buyout

WILMINGTON, Del., March 04, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Five Prime Therapeutics, Inc. (“Five Prime”) (NASDAQ GS: FPRX ) regarding possible breaches...

FPRX : 38.00 (+0.03%)
AMGN : 283.74 (+0.12%)
FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Five Prime...

FPRX : 38.00 (+0.03%)
AMGN : 283.74 (+0.12%)
Five Prime Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Five Prime Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FPRX

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) to Amgen Inc. for $38.00 per share in cash is fair to Five Prime shareholders....

FPRX : 38.00 (+0.03%)
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement...

AMGN : 283.74 (+0.12%)
FPRX : 38.00 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 38.08
2nd Resistance Point 38.05
1st Resistance Point 38.02
Last Price 38.00
1st Support Level 37.96
2nd Support Level 37.93
3rd Support Level 37.90

See More

52-Week High 38.90
Last Price 38.00
Fibonacci 61.8% 25.04
Fibonacci 50% 20.76
Fibonacci 38.2% 16.47
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar